A Harvard researcher has spent a decade chasing a hunch about lithium—not the psychiatric medication, but the element itself in the brain. The work has just yielded something unexpected: evidence that lithium depletion might be one of the earliest signs of Alzheimer's, and that restoring it could slow or even reverse the disease.
Bruce Yankner, a professor of genetics and neurology at Harvard Medical School, discovered that amyloid plaques—those sticky protein clumps that accumulate in Alzheimer's brains—actively bind to lithium and trap it. As lithium becomes scarcer, the brain loses its natural ability to maintain healthy neurons. When his team deliberately depleted lithium in mouse brains, the disease accelerated and memory dissolved. When they restored it using a novel compound called lithium orotate, the damage reversed.
The finding matters because it reframes Alzheimer's as something potentially preventable, not just treatable. "I try to provide hope," Yankner said in a recent interview. "Many people are waiting for this."
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxYankner's work didn't emerge from nowhere. In the 1990s, he was among the first to prove that amyloid wasn't just a harmless byproduct of aging—it was actively toxic to neurons. That discovery reshaped the entire field and led directly to the amyloid-targeting drugs that have recently won FDA approval. This new finding about lithium is the next chapter in the same story.
The path from mouse brain to human clinic is never straight. Yankner's team is now partnering on a clinical trial of lithium orotate, expected to launch this spring. The trial will answer the questions that matter most: Is it safe in humans. Does it actually work. How much do you need.
For now, the message is measured. Yankner is careful to caution people against self-medicating with lithium supplements. The science is real, but it's still preliminary—and lithium at high doses carries real risks. What's changed is that we now have a plausible mechanism and early evidence pointing toward a path forward. That's enough to justify the clinical trial, and enough to explain why people are waiting.
